For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$8.37
Thesis
Telix Pharmaceuticals is a commercial radiopharmaceutical company built on an approved prostate cancer imaging agent. Diagnostic revenue funds a broadening therapeutic radioligand pipeline across oncology.
Catalysts
- Illuccix commercial growth
- Kidney and additional diagnostic approvals
- Therapeutic radioligand program advancement
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Oct 21Financial resultsSEC
Telix Pharmaceuticals files 6-K containing Q3 2026 results announcement.
- Sep 30RegulatorySEC
6-K reports FDA Fast Track designation for BiPass program.
- Sep 21PartnershipSEC
Telix Pharmaceuticals files 6-K on collaboration with ITM.
- Sep 14RegulatorySEC
Telix Pharmaceuticals 6-K reports FDA approval of Pixclara.
- Sep 11RegulatoryFDA
FDA approval of original NDA218592 for PIXCLARA (status date 2026-09-11)
- Sep 2Trial initiationSEC
6-K filing on Phase 3 BIPASS trial enrollment update.
- Sep 1LeadershipSEC
6-K reports appointment of David at Telix Pharmaceuticals Limited.
- Aug 20Financial resultsSEC
Telix Pharmaceuticals files 6-K report covering period ended June 30, 2026.